[Treatment of psoriasis].
About two per cent of the Scandinavian population have manifest psoriasis, which may vary in distribution and duration. With a chronic progressive disease such as psoriasis, it is especially important to weigh the effect of treatment against its tolerance by the patient and the risk of side effects. Recent advances in pharmacology have markedly increased the range of treatment available in severe cases of psoriasis, and the recent introduction of local treatment with vitamin D has resulted in a broader range of treatment for patients with mild or moderate psoriasis. However, no curative treatment is yet within sight.
Kragballe
K
K
Dermatologisk afd, Marselisborg Hospital, Arhus.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000875:Anthralin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids / Q000627:therapeutic use; D013638:Tars / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014807:Vitamin D / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D012176:Retinoids; D013638:Tars; D014807:Vitamin D; D016572:Cyclosporine; D000875:Anthralin; D008727:Methotrexate